These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29297979)

  • 1. Development of predictive signatures for treatment selection in precision medicine with survival outcomes.
    Chen YC; Lee UJ; Tsai CA; Chen JJ
    Pharm Stat; 2018 Mar; 17(2):105-116. PubMed ID: 29297979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subgroup identification for treatment selection in biomarker adaptive design.
    Lu TP; Chen JJ
    BMC Med Res Methodol; 2015 Dec; 15():105. PubMed ID: 26646831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ensemble survival trees for identifying subpopulations in personalized medicine.
    Chen YC; Chen JJ
    Biom J; 2016 Sep; 58(5):1151-63. PubMed ID: 27073016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Subgroup identification based on an accelerated failure time model combined with adaptive elastic net].
    Kang P; Xu J; Huang F; Liu Y; An S
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Oct; 39(10):1200-1206. PubMed ID: 31801710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints.
    Gu X; Yin G; Lee JJ
    Contemp Clin Trials; 2013 Nov; 36(2):642-50. PubMed ID: 24075829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
    Li W; Chen C; Li X; Beckman RA
    Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicine.
    Belhechmi S; Le Teuff G; De Bin R; Rotolo F; Michiels S
    BMC Bioinformatics; 2023 Mar; 24(1):96. PubMed ID: 36927444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations.
    Huber C; Benda N; Friede T
    Pharm Stat; 2019 Oct; 18(5):600-626. PubMed ID: 31270933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Auxiliary variable-enriched biomarker-stratified design.
    Wang T; Wang X; Zhou H; Cai J; George SL
    Stat Med; 2018 Dec; 37(30):4610-4635. PubMed ID: 30221368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cox proportional hazards regression in small studies of predictive biomarkers.
    Jóźwiak K; Nguyen VH; Sollfrank L; Linn SC; Hauptmann M
    Sci Rep; 2024 Jun; 14(1):14232. PubMed ID: 38902269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A subgroup cluster-based Bayesian adaptive design for precision medicine.
    Guo W; Ji Y; Catenacci DVT
    Biometrics; 2017 Jun; 73(2):367-377. PubMed ID: 27775814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A promising subgroup identification method based on a genetic algorithm for censored survival data.
    Zhao L; Zhang W; Wu Y; Cao L; Wang L; Li K
    J Biopharm Stat; 2024 Jan; 34(1):55-77. PubMed ID: 36727221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Permutation-based variance component test in generalized linear mixed model with application to multilocus genetic association study.
    Zeng P; Zhao Y; Li H; Wang T; Chen F
    BMC Med Res Methodol; 2015 Apr; 15():37. PubMed ID: 25897803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Point estimation in adaptive enrichment designs.
    Kunzmann K; Benner L; Kieser M
    Stat Med; 2017 Nov; 36(25):3935-3947. PubMed ID: 28783881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.
    Dreyling M; Ferrero S;
    Haematologica; 2015 Jun; 100(6):706-8. PubMed ID: 26034112
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of Variable Selection Methods for Time-to-Event Data in High-Dimensional Settings.
    Gilhodes J; Dalenc F; Gal J; Zemmour C; Leconte E; Boher JM; Filleron T
    Comput Math Methods Med; 2020; 2020():6795392. PubMed ID: 32670394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
    Mendell J; Freeman DJ; Feng W; Hettmann T; Schneider M; Blum S; Ruhe J; Bange J; Nakamaru K; Chen S; Tsuchihashi Z; von Pawel J; Copigneaux C; Beckman RA
    EBioMedicine; 2015 Mar; 2(3):264-71. PubMed ID: 26137564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal decision rules for biomarker-based subgroup selection for a targeted therapy in oncology.
    Krisam J; Kieser M
    Int J Mol Sci; 2015 May; 16(5):10354-75. PubMed ID: 25961947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers.
    Zhang Y; Trippa L; Parmigiani G
    Biometrics; 2016 Jun; 72(2):414-21. PubMed ID: 26575199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.